Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.49 |
| ▸ | PRCP | P42785 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18373952 | 0.92 | ACE (0.52) | ACEACE2PRCPOPRD1OPRM1 | |
| SCHEMBL28918691 | 0.92 | ACE (0.52) | ACEACE2PRCPOPRD1OPRM1 | |
| SCHEMBL28918688 | 0.90 | ACE (0.54) | ACEACE2PRCPOPRD1OPRM1 | |
| SCHEMBL28918687 | 0.90 | ACE (0.54) | ACEACE2PRCPOPRD1OPRM1 | |
| SCHEMBL31159646 | 0.87 | ACE (0.51) | ACEACE2PRCPOPRD1OPRM1 | |
| SCHEMBL21302901 | 0.87 | ACE (0.51) | ACEACE2PRCPOPRD1OPRM1 | |
| SCHEMBL20415563 | 0.85 | CMA1 (0.51) | ACE | |
| SCHEMBL28918709 | 0.85 | ACE (0.51) | ACEACE2OPRD1OPRM1GRIA1 | |
| SCHEMBL28918692 | 0.85 | ACE (0.51) | ACEACE2OPRD1OPRM1GRIA1 | |
| SCHEMBL18374383 | 0.84 | OPRM1 (0.50) | OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230018246-A1 | PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME | Research & Business Foundation Sungkyunkwan University (KR) | 2023-01-19 | — | — | US | disclosed |
| US-11365215-B2 | Method for preventing, improving, or treating inflammatory bowel disease | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-06-21 | — | — | US | disclosed |
| US-20180208625-A1 | METHOD FOR PREVENTING, IMPROVING, OR TREATING INFLAMMATORY BOWEL DISEASE | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-07-26 | — | — | US | disclosed |
| US-20170008924-A1 | PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME | Research & Business Foundation Sungkyunkwan University (KR) | 2017-01-12 | — | — | US | disclosed |
| WO-2017008033-A1 | PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME | Reasearch & Business Foundation Sungkyunkwan University (KR) | 2017-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208625-A1 | METHOD FOR PREVENTING, IMPROVING, OR TREATING INFLAMMATORY BOWEL DISEASE | SI, NOD2, TNF | ACE 1039/4885ACE2 1532/4885PRCP 1398/4885 |
| US-20170008924-A1 | PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME | NOD2, SI, APC | ACE 1293/4885ACE2 1072/4885PRCP 399/4885 |
| US-11365215-B2 | Method for preventing, improving, or treating inflammatory bowel disease | SI, NOD2, TNF | ACE 1039/4885ACE2 1532/4885PRCP 1398/4885 |
| US-20230018246-A1 | PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME | NOD2, SI, APC | ACE 1293/4885ACE2 1072/4885PRCP 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.